AU2003231082A1 - Controlled release compositions of estradiol metabolites - Google Patents
Controlled release compositions of estradiol metabolitesInfo
- Publication number
- AU2003231082A1 AU2003231082A1 AU2003231082A AU2003231082A AU2003231082A1 AU 2003231082 A1 AU2003231082 A1 AU 2003231082A1 AU 2003231082 A AU2003231082 A AU 2003231082A AU 2003231082 A AU2003231082 A AU 2003231082A AU 2003231082 A1 AU2003231082 A1 AU 2003231082A1
- Authority
- AU
- Australia
- Prior art keywords
- estradiol metabolites
- sustained release
- present
- compositions
- hydroxyestradiol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 238000013270 controlled release Methods 0.000 title 1
- VOXZDWNPVJITMN-WKUFJEKOSA-N estradiol group Chemical group [C@@H]12CCC(O)[C@@]1(C)CC[C@@H]1C3=C(CC[C@@H]21)C=C(O)C=C3 VOXZDWNPVJITMN-WKUFJEKOSA-N 0.000 title 1
- 150000002159 estradiols Chemical class 0.000 abstract 4
- 239000012730 sustained-release form Substances 0.000 abstract 3
- 238000009472 formulation Methods 0.000 abstract 2
- 238000013268 sustained release Methods 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- DILDHNKDVHLEQB-XSSYPUMDSA-N 2-hydroxy-17beta-estradiol Chemical compound OC1=C(O)C=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 DILDHNKDVHLEQB-XSSYPUMDSA-N 0.000 abstract 1
- CQOQDQWUFQDJMK-SSTWWWIQSA-N 2-methoxy-17beta-estradiol Chemical compound C([C@@H]12)C[C@]3(C)[C@@H](O)CC[C@H]3[C@@H]1CCC1=C2C=C(OC)C(O)=C1 CQOQDQWUFQDJMK-SSTWWWIQSA-N 0.000 abstract 1
- QOZFCKXEVSGWGS-ZHIYBZGJSA-N 4-hydroxy-17beta-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1O QOZFCKXEVSGWGS-ZHIYBZGJSA-N 0.000 abstract 1
- BCWZIZLVBYHFES-PYEWSWHRSA-N 4-methoxy-17beta-estradiol Chemical compound C([C@@H]12)C[C@]3(C)[C@@H](O)CC[C@H]3[C@@H]1CCC1=C2C=CC(O)=C1OC BCWZIZLVBYHFES-PYEWSWHRSA-N 0.000 abstract 1
- 241000272173 Calidris Species 0.000 abstract 1
- 230000036765 blood level Effects 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- 239000010408 film Substances 0.000 abstract 1
- 239000000499 gel Substances 0.000 abstract 1
- 239000000017 hydrogel Substances 0.000 abstract 1
- 239000007943 implant Substances 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 239000002502 liposome Substances 0.000 abstract 1
- 239000007937 lozenge Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000003094 microcapsule Substances 0.000 abstract 1
- 239000011859 microparticle Substances 0.000 abstract 1
- 239000002088 nanocapsule Substances 0.000 abstract 1
- 239000002105 nanoparticle Substances 0.000 abstract 1
- -1 patches Substances 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 239000006213 vaginal ring Substances 0.000 abstract 1
- 235000012431 wafers Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Nanotechnology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60/377,490 | 2002-05-02 | ||
| US37749002P | 2002-05-03 | 2002-05-03 | |
| PCT/US2003/012727 WO2003092585A2 (en) | 2002-05-02 | 2003-04-25 | Controlled release compositions of estradiol metabolites |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2003231082A8 AU2003231082A8 (en) | 2003-11-17 |
| AU2003231082A1 true AU2003231082A1 (en) | 2003-11-17 |
Family
ID=29401508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003231082A Abandoned AU2003231082A1 (en) | 2002-05-02 | 2003-04-25 | Controlled release compositions of estradiol metabolites |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20060083778A1 (enExample) |
| EP (1) | EP1507514B1 (enExample) |
| JP (1) | JP2005525403A (enExample) |
| AT (1) | ATE353632T1 (enExample) |
| AU (1) | AU2003231082A1 (enExample) |
| DE (1) | DE60311801T2 (enExample) |
| WO (1) | WO2003092585A2 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040157816A1 (en) * | 2002-08-26 | 2004-08-12 | Girouard Michael P. | Monounsaturated fatty acids and perhydrocyclopentanophenanthrene nucleus combination molecules, and their precursors, and the use of all of these as weight-loss agents |
| EP1829529A1 (en) * | 2002-05-03 | 2007-09-05 | PR Pharmaceuticals, Inc. | Controlled release compositions of estradiol metabolites |
| US20040082558A1 (en) * | 2002-08-02 | 2004-04-29 | Tofovic Stevan P. | Administration of estradiol metabolites for inhibition of drug-induced nephrotoxicity |
| JP2007515392A (ja) | 2003-04-10 | 2007-06-14 | ピーアール ファーマシューティカルズ，インコーポレイテッド | エマルジョンベースの微粒子の製造のための方法 |
| ES2625343T3 (es) | 2003-07-15 | 2017-07-19 | Evonik Corporation | Método para la preparación de formulaciones de liberación controlada |
| CA2533592C (en) | 2003-07-23 | 2015-11-10 | Pr Pharmaceuticals, Inc. | Controlled release compositions |
| US20050106214A1 (en) * | 2003-11-14 | 2005-05-19 | Guohua Chen | Excipients in drug delivery vehicles |
| US20060057216A1 (en) * | 2004-09-15 | 2006-03-16 | Salamone Joseph C | Low-obscuration image transmitting particulate ocular therapeutic formulations |
| CN101115471B (zh) * | 2005-02-17 | 2011-02-09 | 梅迪沃什有限公司 | 聚合物颗粒输送组合物及使用方法 |
| US20090280064A1 (en) * | 2005-06-24 | 2009-11-12 | Rao Papineni | Transdermal delivery of optical, spect, multimodal, drug or biological cargo laden nanoparticle(s) in small animals or humans |
| US9486408B2 (en) | 2005-12-01 | 2016-11-08 | University Of Massachusetts Lowell | Botulinum nanoemulsions |
| US20100150994A1 (en) | 2006-12-01 | 2010-06-17 | Anterios, Inc. | Amphiphilic entity nanoparticles |
| EP2091516A2 (en) | 2006-12-01 | 2009-08-26 | Anterios, Inc. | Peptide nanoparticles and uses therefor |
| KR20150028856A (ko) | 2007-05-31 | 2015-03-16 | 안테리오스, 인코퍼레이티드 | 핵산 나노입자 및 이의 용도 |
| EP2196194B1 (en) * | 2007-09-10 | 2017-08-09 | M Technique Co., Ltd. | Process for producing biological ingesta and biological ingesta obtained thereby |
| US20120015017A1 (en) * | 2009-05-19 | 2012-01-19 | Nyden Bo Magnus | Slow releasing microcapsules containing an active substance |
| US20110275686A1 (en) * | 2009-12-11 | 2011-11-10 | Biolitec, Inc. | Nanoparticle carrier systems based on poly(dl-lactic-co-glycolic acid) (plga) for photodynamic therapy (pdt) |
| CN101953774B (zh) * | 2010-09-17 | 2011-11-23 | 郑州大学 | 2-甲氧基雌二醇可注射水凝胶植入剂 |
| US8580294B2 (en) | 2010-10-19 | 2013-11-12 | International Partnership For Microbicides | Platinum-catalyzed intravaginal rings |
| BR112014012444B1 (pt) | 2011-11-23 | 2021-12-14 | Therapeuticsmd, Inc | Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| KR102005579B1 (ko) * | 2012-11-19 | 2019-07-30 | 가톨릭대학교 산학협력단 | 세포배양용 다공성 지지체 및 이의 제조방법 |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US10227369B2 (en) | 2013-03-12 | 2019-03-12 | The Johns Hopkins University | Short-chain fatty acid hexosamine analogs and their use in tissue engineering applications |
| GB2521334B (en) * | 2013-08-21 | 2018-06-20 | Univ Swansea | Topical drug patch including microspheres |
| US10137031B2 (en) | 2013-11-14 | 2018-11-27 | International Partnership For Microbicides, Inc. | Combination therapy intravaginal rings |
| CL2013003807A1 (es) * | 2013-12-31 | 2014-07-11 | Univ Santiago Chile | Dispositivos de tubos pequeños de silicona que contienen nanopartículas y micropartículas de zeolitas como agentes de liberación prolongada y controlada, cargadas con 2-metoxiestradiol y suspendidas en un medio oleoso que también contiene 2-metoxiestradiol. |
| RU2016143081A (ru) | 2014-05-22 | 2018-06-26 | Терапьютиксмд, Инк. | Натуральные комбинированные гормонозаместительные составы и терапии |
| EP3277241B1 (en) | 2015-03-31 | 2023-12-20 | Merck Sharp & Dohme B.V. | Vaginal ring applicator |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| KR20180126582A (ko) | 2016-04-01 | 2018-11-27 | 쎄러퓨틱스엠디, 인코퍼레이티드 | 스테로이드 호르몬 약제학적 조성물 |
| WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
| KR102487144B1 (ko) | 2016-11-21 | 2023-01-12 | 에이리온 테라퓨틱스, 인코포레이티드 | 큰 물질의 경피 전달 |
| JP7296520B2 (ja) * | 2019-03-19 | 2023-06-22 | 株式会社リーゼンバイオテク | ステロイド系薬物を含む生分解性高分子微細粒子及びその製造方法 |
| CN113509448A (zh) * | 2020-07-02 | 2021-10-19 | 安徽中医药大学 | 一种可生物降解控释长效植入片及其制备方法 |
| CN116059181A (zh) * | 2022-09-26 | 2023-05-05 | 上海交通大学医学院附属新华医院 | 一种纳米药物递送系统 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5288496A (en) * | 1990-05-15 | 1994-02-22 | Stolle Research & Development Corporation | Growth promoters for animals |
| HU222501B1 (hu) * | 1991-06-28 | 2003-07-28 | Endorecherche Inc. | MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására |
| US5643595A (en) * | 1992-11-24 | 1997-07-01 | Alkermes Controlled Therapeutics Inc. Ii | Growth promoters for animals |
| CN1156961A (zh) * | 1995-06-09 | 1997-08-13 | 欧罗赛铁克股份有限公司 | 产生长效局部麻醉的制剂和方法 |
| US5985309A (en) * | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| US5855913A (en) * | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US6495579B1 (en) * | 1996-12-02 | 2002-12-17 | Angiotech Pharmaceuticals, Inc. | Method for treating multiple sclerosis |
| WO1998046212A1 (en) * | 1997-04-17 | 1998-10-22 | Amgen Inc. | Biodegradable microparticles for the sustained delivery of therapeutic drugs |
| AUPQ342599A0 (en) * | 1999-10-14 | 1999-11-04 | University Of Melbourne, The | Conjugates and uses thereof |
| US6743446B2 (en) * | 1999-12-15 | 2004-06-01 | The Ohio State University Research Foundation | Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers |
| JP2005501096A (ja) * | 2001-08-17 | 2005-01-13 | ユニヴァーシティ オブ ピッツバーグ | 肥満、代謝症候群、糖尿病、血管障害及び腎臓疾患を治療又は予防するエストラジオールメタボライトの投与 |
-
2003
- 2003-04-25 US US10/513,542 patent/US20060083778A1/en not_active Abandoned
- 2003-04-25 DE DE60311801T patent/DE60311801T2/de not_active Expired - Fee Related
- 2003-04-25 EP EP03724207A patent/EP1507514B1/en not_active Expired - Lifetime
- 2003-04-25 AT AT03724207T patent/ATE353632T1/de not_active IP Right Cessation
- 2003-04-25 WO PCT/US2003/012727 patent/WO2003092585A2/en not_active Ceased
- 2003-04-25 JP JP2004500770A patent/JP2005525403A/ja active Pending
- 2003-04-25 AU AU2003231082A patent/AU2003231082A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003231082A8 (en) | 2003-11-17 |
| EP1507514A4 (en) | 2005-08-10 |
| DE60311801T2 (de) | 2007-11-08 |
| WO2003092585A2 (en) | 2003-11-13 |
| JP2005525403A (ja) | 2005-08-25 |
| US20060083778A1 (en) | 2006-04-20 |
| EP1507514A2 (en) | 2005-02-23 |
| ATE353632T1 (de) | 2007-03-15 |
| EP1507514B1 (en) | 2007-02-14 |
| DE60311801D1 (de) | 2007-03-29 |
| WO2003092585A3 (en) | 2004-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003231082A1 (en) | Controlled release compositions of estradiol metabolites | |
| Herculano et al. | On the release of metronidazole from natural rubber latex membranes | |
| JP2974969B2 (ja) | 経皮ドラッグデリバリーのための固体マトリックスシステム | |
| NO975708L (no) | Blanding for vedvarende frigjöring av humant veksthormon | |
| JP2018065859A (ja) | 癌を治療するための方法及び組成物 | |
| HUP0102785A2 (hu) | Matrix típusú, transzdermális hatóanyag-szolgáltató rendszer szteroid hormonok felszabadítására | |
| MX2007000273A (es) | Composiciones de liberacion sostenida que contiene moduladores del receptor de progesterona. | |
| HUP9800863A2 (hu) | Gyógyszerszállító rendszer két vagy több hatóanyaghoz | |
| WO2007050724A3 (en) | Lipophilic vehicle-based dual controlled release matrix system as capsule fill | |
| JP2010520888A (ja) | 神経変性の治療としてのニトロキシドラジカル | |
| BR9815512A (pt) | Sistema terapêutico transdérmico (tts), paraadministração transcutânea de esteróidessexuais e método para a produção de um tts | |
| AU1046302A (en) | Transdermal therapeutic system | |
| JP2002509879A (ja) | 水分により活性化可能な治療システム | |
| PT1896034E (pt) | Composições de tanaproget micronizado e métodos para a sua preparação | |
| SI1534352T1 (sl) | Vsadek za transport in sproščanje farmakoloških učinkovin, kot tudi postopek za proizvodnjo le-tega | |
| JP2008521904A (ja) | 置換ベンゾオキサゾールの製剤 | |
| KR20070089921A (ko) | 치환된 벤족사졸의 제형 | |
| US20060121111A1 (en) | Formulations of substituted benzoxazoles | |
| JP2022507102A (ja) | イブプロフェンまたはその構造類似体を含む多層経皮薬物送達システム | |
| WO2003080018A1 (en) | Intravaginal matrix drug delivery devices | |
| WO2004112837A1 (ja) | 非ステロイド系消炎鎮痛剤含有外用経皮製剤およびインターロイキン－１α生成抑制剤 | |
| NO20063805L (no) | Hoyrent butokonazolnitrat med spesifisert partikkelstorrelse og en fremgangsmate for fremstilling derav | |
| ECSP056190A (es) | Compuestos utiles en la terapia de la enfermedad de alzheimer y formulaciones que los contienen | |
| TWI726956B (zh) | 製造藥物遞送裝置之方法及根據該方法製造之藥物遞送裝置 | |
| DE50202865D1 (de) | Herstellung reiner stereoisomere von tricyclo-[5.2.1.0(2.6) ]-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |